Please assess the completion status of the following clinical trial:

Trial Title: Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed double-blind portion of the IM101064 study.~* Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis~* American College of Rheumatology (ACR) functional class I, II, III~* Subjects currently or previously received an anti-TNF therapy at an approved labeled dose for at least 3 months~Exclusion Criteria:~* Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules)~* History of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label Abatacept (ABA)-Previous User (Type: EXPERIMENTAL): In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
- Open-label ABA-Current User (Type: EXPERIMENTAL): In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
- Long-term ABA (Type: EXPERIMENTAL): Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.

Based on this trial design, predict the completion outcome and termination type (if applicable).